JPWO2021207669A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021207669A5 JPWO2021207669A5 JP2022561460A JP2022561460A JPWO2021207669A5 JP WO2021207669 A5 JPWO2021207669 A5 JP WO2021207669A5 JP 2022561460 A JP2022561460 A JP 2022561460A JP 2022561460 A JP2022561460 A JP 2022561460A JP WO2021207669 A5 JPWO2021207669 A5 JP WO2021207669A5
- Authority
- JP
- Japan
- Prior art keywords
- acc
- monomer
- optionally
- combination
- monomer construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000178 monomer Substances 0.000 claims 41
- 102000004127 Cytokines Human genes 0.000 claims 19
- 108090000695 Cytokines Proteins 0.000 claims 19
- 230000000694 effects Effects 0.000 claims 18
- 238000006471 dimerization reaction Methods 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 8
- 108010050904 Interferons Proteins 0.000 claims 6
- 102000014150 Interferons Human genes 0.000 claims 6
- 108091005804 Peptidases Proteins 0.000 claims 6
- 239000004365 Protease Substances 0.000 claims 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 229940079322 interferon Drugs 0.000 claims 5
- 230000009467 reduction Effects 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 239000000539 dimer Substances 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 101150044980 Akap1 gene Proteins 0.000 claims 1
- 108010016529 Bacillus amyloliquefaciens ribonuclease Proteins 0.000 claims 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims 1
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 claims 1
- 108010005730 R-SNARE Proteins Proteins 0.000 claims 1
- 102000000583 SNARE Proteins Human genes 0.000 claims 1
- 108010041948 SNARE Proteins Proteins 0.000 claims 1
- 102000002215 Synaptobrevin Human genes 0.000 claims 1
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 claims 1
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 claims 1
- 102000050389 Syntaxin Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000056003 human IL15 Human genes 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000003032 molecular docking Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 102000003137 synaptotagmin Human genes 0.000 claims 1
- 108060008004 synaptotagmin Proteins 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008542P | 2020-04-10 | 2020-04-10 | |
| US63/008,542 | 2020-04-10 | ||
| US202163161889P | 2021-03-16 | 2021-03-16 | |
| US63/161,889 | 2021-03-16 | ||
| US202163164849P | 2021-03-23 | 2021-03-23 | |
| US63/164,849 | 2021-03-23 | ||
| PCT/US2021/026675 WO2021207669A1 (en) | 2020-04-10 | 2021-04-09 | Activatable cytokine constructs and related compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023520922A JP2023520922A (ja) | 2023-05-22 |
| JPWO2021207669A5 true JPWO2021207669A5 (https=) | 2024-04-19 |
| JP2023520922A5 JP2023520922A5 (https=) | 2024-04-19 |
Family
ID=75747127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022561460A Pending JP2023520922A (ja) | 2020-04-10 | 2021-04-09 | 活性化可能サイトカイン構築物および関連組成物ならびに方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11365233B2 (https=) |
| EP (1) | EP4133085A1 (https=) |
| JP (1) | JP2023520922A (https=) |
| KR (1) | KR20220167295A (https=) |
| CN (1) | CN115667523B (https=) |
| AU (2) | AU2021254283B2 (https=) |
| BR (1) | BR112022020440A2 (https=) |
| CA (1) | CA3174786A1 (https=) |
| IL (1) | IL297225A (https=) |
| MX (1) | MX2022012592A (https=) |
| WO (1) | WO2021207669A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| JP2024511387A (ja) * | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| US20240384323A1 (en) | 2021-08-30 | 2024-11-21 | Cytomx Therapeutics, Inc. | Method for determining protease activity in a biological sample |
| AU2022361492A1 (en) * | 2021-10-08 | 2024-05-02 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| CA3245158A1 (en) * | 2022-03-03 | 2023-09-07 | The Trustees Of The University Of Pennsylvania | Viral vectors encoding parathyroid hormone fusions and uses thereof in treating hypoparathyroidism |
| WO2023183888A1 (en) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| US20250333487A1 (en) | 2022-03-25 | 2025-10-30 | Cytomx Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| JP2025511187A (ja) | 2022-04-01 | 2025-04-15 | サイトムエックス セラピューティクス，インク． | Ｃｄ３結合タンパク質及びその使用方法 |
| TW202424183A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割受質及其使用方法 |
| JP2025525879A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性基質及びその使用方法 |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| US20260042849A1 (en) | 2022-08-01 | 2026-02-12 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| AR130079A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| US20240067691A1 (en) * | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| EP4695281A1 (en) | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216146A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| DE60129695T2 (de) * | 2000-06-29 | 2008-06-05 | Merck Patent Gmbh | Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| ATE513563T1 (de) | 2000-10-09 | 2011-07-15 | Isis Innovation | Therapeutische und toleranz-induzierende antikörper |
| US6942853B2 (en) | 2001-01-09 | 2005-09-13 | Queen Mary And Westfield College | Latent fusion protein |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| US20060024272A1 (en) | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
| MX2007014889A (es) * | 2005-05-26 | 2008-02-19 | Schering Corp | Fusion de interferon-inmunoglobulina g. |
| JP2009529522A (ja) | 2006-03-10 | 2009-08-20 | ディアト | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 |
| CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| WO2009079837A1 (en) | 2007-12-18 | 2009-07-02 | Hangzhou Jiuyuan Gene Engineering Co., Ltd. | A pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| JP5861223B2 (ja) | 2009-02-23 | 2016-02-16 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | プロタンパク質およびその使用方法 |
| EP2553101A4 (en) | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| HRP20150664T1 (hr) | 2010-12-03 | 2015-07-31 | Adamed Sp. Z O.O. | Antikancerogeni fuzijski protein |
| HRP20200470T1 (hr) | 2011-01-18 | 2020-10-02 | Bioniz, Llc | Pripravci za modulaciju aktivnosti gama-c-citokina |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| EP2854845B1 (en) * | 2012-06-01 | 2018-03-28 | IBC Pharmaceuticals, Inc. | Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy |
| CA2925106C (en) | 2013-09-25 | 2023-11-14 | Cytomx Therapeutics, Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| IL270562B (en) * | 2014-01-31 | 2022-08-01 | Cytomx Therapeutics Inc | Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses |
| GB201411506D0 (en) * | 2014-06-27 | 2014-08-13 | Univ London Queen Mary | Modified latency associated protein construct |
| RS59340B1 (sr) | 2014-11-06 | 2019-10-31 | Hoffmann La Roche | Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| JP2019518786A (ja) | 2016-05-06 | 2019-07-04 | 牧林 王 | インターロイキンの組み合せ及びその使用 |
| CN110214147A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15Rα异源二聚体FC-融合蛋白 |
| CN111050803A (zh) | 2017-06-20 | 2020-04-21 | 德克萨斯大学系统董事会 | 用于治疗癌症的干扰素前药 |
| CA3287794A1 (en) | 2017-10-14 | 2025-10-27 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| CA3081539A1 (en) | 2017-11-08 | 2019-05-16 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
| CN111954680B (zh) | 2017-11-10 | 2024-03-15 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| EP3727146A4 (en) | 2017-12-19 | 2021-10-06 | Blaze Bioscience, Inc. | TUMOR HOMING AND CELL-PENETANT PEPTIDE IMMUNO-ONCOLOGY AGENT COMPLEX AND METHOD OF USE |
| WO2020113403A1 (en) | 2018-12-04 | 2020-06-11 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| WO2019173832A2 (en) | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| WO2019230868A1 (ja) | 2018-05-30 | 2019-12-05 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
| US12030721B2 (en) | 2018-06-21 | 2024-07-09 | Tgw Logistics Group Gmbh | Storage and order picking system and method for picking ordered articles from a hanging bag and another load aid |
| EP3810624A4 (en) | 2018-06-22 | 2022-07-06 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CN112867503A (zh) | 2018-08-24 | 2021-05-28 | 希望之城 | 掩蔽的细胞因子缀合物 |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| JP2022502443A (ja) | 2018-09-28 | 2022-01-11 | ピエール、ファーブル、メディカマン | 癌の処置のための新規な免疫サイトカイン |
| AU2019366956B2 (en) | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
| MY205459A (en) | 2018-12-06 | 2024-10-22 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| AU2019395266A1 (en) | 2018-12-14 | 2021-06-17 | Proviva Therapeutics (Hong Kong) Limited | IL-15 compositions and methods of use thereof |
| WO2020214690A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| JP2022533254A (ja) | 2019-05-24 | 2022-07-21 | プロヴィヴァ セラピューティクス （ホン コン） リミテッド | Ｉｌ－２組成物およびその使用方法 |
| CN114127277A (zh) | 2019-06-05 | 2022-03-01 | 中外制药株式会社 | 蛋白酶底物和包含蛋白酶切割序列的多肽 |
| KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
| CA3146156A1 (en) | 2019-07-12 | 2021-01-21 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
| MX2022000991A (es) | 2019-07-25 | 2022-05-24 | Univ Chicago | Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa. |
| EP4004026A4 (en) | 2019-07-25 | 2023-11-15 | Trutino Biosciences Inc. | IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER |
| CA3148505A1 (en) | 2019-08-12 | 2021-02-18 | AskGene Pharma, Inc. | Novel il-2 fusion molecules |
| US20220289822A1 (en) | 2019-08-21 | 2022-09-15 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| US20220356221A1 (en) | 2019-09-28 | 2022-11-10 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| CN115315434A (zh) | 2019-12-05 | 2022-11-08 | 免疫靶向有限公司 | 白细胞介素15融合蛋白和前药及其组合物和方法 |
| MX2022007202A (es) | 2019-12-13 | 2022-10-07 | Cugene Inc | Fármacos bioactivables a base de citocinas y metodos de uso de los mismos. |
| BR112022012112A2 (pt) | 2019-12-20 | 2022-09-06 | Regeneron Pharma | Agonistas de il2 e métodos de uso dos mesmos |
| US20240043489A1 (en) | 2020-01-15 | 2024-02-08 | Trutino Biosciences Inc. | Cytokine Prodrugs Comprising a Cleavable Linker |
| JP7773991B2 (ja) | 2020-03-23 | 2025-11-20 | ザイムワークス ビーシー インコーポレイテッド | マスクされたｉｌ１２融合タンパク質及びその使用方法 |
| WO2021202354A1 (en) | 2020-03-30 | 2021-10-07 | Proviva Therapeutics (Hong Kong) Limited | Il-2/il-15 compositions and methods of use thereof |
| AU2021248919A1 (en) | 2020-04-01 | 2022-10-13 | Xilio Development, Inc. | Masked IL-12 cytokines and their cleavage products |
| JP7735306B2 (ja) | 2020-04-01 | 2025-09-08 | エクシリオ デベロップメント， インコーポレイテッド | マスクされたｉｌ－２サイトカイン及びその切断産物 |
| IL296911A (en) | 2020-04-01 | 2022-12-01 | Xilio Dev Inc | Masked il-15 cytokines and their cleavage products |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| US11597753B2 (en) | 2020-04-30 | 2023-03-07 | Immune Targeting, Inc. | Activatable IL2 composition and methods of use |
| JP2023526428A (ja) | 2020-05-19 | 2023-06-21 | ウェアウルフ セラピューティクス， インコーポレイテッド | 活性化可能なｉｌ－１２ポリペプチド及びその使用方法 |
| JP2024511387A (ja) | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| EP4695281A1 (en) * | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
-
2021
- 2021-04-09 AU AU2021254283A patent/AU2021254283B2/en active Active
- 2021-04-09 CA CA3174786A patent/CA3174786A1/en active Pending
- 2021-04-09 BR BR112022020440A patent/BR112022020440A2/pt unknown
- 2021-04-09 MX MX2022012592A patent/MX2022012592A/es unknown
- 2021-04-09 CN CN202180030934.8A patent/CN115667523B/zh active Active
- 2021-04-09 IL IL297225A patent/IL297225A/en unknown
- 2021-04-09 KR KR1020227037537A patent/KR20220167295A/ko active Pending
- 2021-04-09 WO PCT/US2021/026675 patent/WO2021207669A1/en not_active Ceased
- 2021-04-09 EP EP21722711.5A patent/EP4133085A1/en active Pending
- 2021-04-09 JP JP2022561460A patent/JP2023520922A/ja active Pending
- 2021-04-09 US US17/227,017 patent/US11365233B2/en active Active
-
2022
- 2022-05-25 US US17/824,294 patent/US12091442B2/en active Active
-
2024
- 2024-08-15 US US18/806,635 patent/US20250179141A1/en active Pending
-
2026
- 2026-01-12 AU AU2026200173A patent/AU2026200173A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021207669A5 (https=) | ||
| KR100484084B1 (ko) | 키메라성 폴리펩타이드, 이의 제조 방법 및 용도 | |
| AU736707B2 (en) | Trimerising module | |
| Batra et al. | Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR (Fv)-PE40 and DT388-anti-TFR (Fv) | |
| EP2420253A1 (en) | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain | |
| AU2026200173A1 (en) | Activatable Cytokine Constructs And Related Compositions And Methods | |
| JP5077924B2 (ja) | 分泌された三量体受容体類似体及び生物学的活性融合タンパク質を製造するための方法及び組成物 | |
| JPH08277227A (ja) | 上皮細胞に特異的な成長因子をコードするｄｎａ | |
| JP2012520059A5 (https=) | ||
| EP2646472B1 (en) | Covalently dimerized bivalent binding agents | |
| JP2021527700A5 (https=) | ||
| JPH11504819A (ja) | 新規の変異型ｃｄ４０ｌ | |
| JPWO2020232305A5 (https=) | ||
| JPWO2021189139A5 (https=) | ||
| JPWO2021202678A5 (https=) | ||
| CN120051292A (zh) | Il-18融合蛋白以及生产il-18的方法 | |
| JPWO2021202675A5 (https=) | ||
| CN106380517B (zh) | 一种对中东呼吸综合征冠状病毒具有中和活性的小分子抗体及其应用 | |
| JPH03503524A (ja) | ミュレル管阻害物質様ポリペプチドの開裂二量体 | |
| Eisenmesser et al. | Expression, purification, refolding, and characterization of recombinant human interleukin-13: utilization of intracellular processing | |
| JPWO2019246508A5 (https=) | ||
| CN114075287B (zh) | 人源化bcma抗体和bcma-car-t细胞 | |
| AU696349B2 (en) | Methods for peptide synthesis and purification | |
| CN102770438A (zh) | 通过在多个单体与特异性结合单体的粘合体的重复链的复合物中增加键桥的产量以生产二聚体和多聚体的方法 | |
| IE71934B1 (en) | Protein anti-cancer agent |